ARRY: Array Technologies, Inc. Stock

by  •  • Comments Off on ARRY: Array Technologies, Inc. Stock

SIC 399 – Miscellaneous Manufacturing Industries

Valuation
Market Cap ($M) 740.31
Enterprise Value ($M) 1,461.53
Book Value ($M) 288.83
Book Value / Share 1.90
Price / Book 2.56
NCAV ($M) -138.44
NCAV / Share -0.91
Price / NCAV -5.35

Profitability (mra)
Return on Invested Capital (ROIC) -0.24
Return on Assets (ROA) -0.15
Return on Equity (ROE) -0.40

Liquidity (mrq)
Quick Ratio 1.82
Current Ratio 2.28

Balance Sheet (mrq) ($M)
Current Assets 998.72
Assets 1,426.00
Liabilities 1,137.16
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 915.81
Operating Income 101.02
Net Income -240.39
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 153.98
Cash from Investing -9.57
Cash from Financing -11.84

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Schroder Investment Management Group 5.30
02-12 13G/A Grantham, Mayo, Van Otterloo & Co. LLC 7.34 37.11
02-11 13G/A Goldman Sachs Group Inc 2.40 -57.73
01-13 13G Point72 Asset Management, L.P. 5.00
11-14 13G/A Electron Capital Partners, LLC 1.20 -76.95
11-12 13G/A BlackRock, Inc. 10.10 0.00
11-12 13G/A Hill City Capital, LP 9.39 61.37

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-03 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-01 633,864 3,441,584 18.42
2025-03-31 643,716 2,665,239 24.15
2025-03-28 667,815 2,473,957 26.99
2025-03-27 566,225 1,941,859 29.16

(click for more detail)


Financial data and stock pages provided by
Fintel.io

Finpedia: Array BioPharma